PTC Therapeutics, Inc. (PTCT) stock
PTCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 5/3028% above fair value
$60.23−0.13 (-0.22%)
Close on Nov 18, 2026Market cap $5.03BP/E –Yield –
PTC Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
PTC Therapeutics's revenue for the twelve months ending Sep 30, 2026 was $1.16B, down 35.1% year over year. For fiscal 2025 it was $1.73B, up 114.5% from the year before. Over ten years it grew 47.0% a year on average. The highest annual figure on record is $1.73B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.73B | +114.5% |
| FY2024 | Dec 31, 2024 | $806.78M | -14.0% |
| FY2023 | Dec 31, 2023 | $937.82M | +34.2% |
| FY2022 | Dec 31, 2022 | $698.80M | +29.7% |
| FY2021 | Dec 31, 2021 | $538.59M | +41.4% |
| FY2020 | Dec 31, 2020 | $380.77M | +24.0% |
| FY2019 | Dec 31, 2019 | $306.98M | +16.0% |
| FY2018 | Dec 31, 2018 | $264.73M | +36.2% |
| FY2017 | Dec 31, 2017 | $194.39M | +135.0% |
| FY2016 | Dec 31, 2016 | $82.71M | +124.9% |
| FY2015 | Dec 31, 2015 | $36.77M | +45.6% |
| FY2014 | Dec 31, 2014 | $25.25M | -27.2% |
| FY2013 | Dec 31, 2013 | $34.70M | +2.2% |
| FY2012 | Dec 31, 2012 | $33.95M | -67.8% |
| FY2011 | Dec 31, 2011 | $105.41M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $357.81M | +69.6% |
| Q2 FY2026 | Jun 30, 2026 | $360.52M | +101.5% |
| Q1 FY2026 | Mar 31, 2026 | $272.55M | -76.8% |
| Q4 FY2025 | Dec 31, 2025 | $164.68M | -22.7% |
| Q3 FY2025 | Sep 30, 2025 | $211.01M | +7.2% |
| Q2 FY2025 | Jun 30, 2025 | $178.88M | -4.2% |
| Q1 FY2025 | Mar 31, 2025 | $1.18B | +459.7% |
| Q4 FY2024 | Dec 31, 2024 | $213.17M | -30.6% |
| Q3 FY2024 | Sep 30, 2024 | $196.79M | +0.1% |
| Q2 FY2024 | Jun 30, 2024 | $186.70M | -12.7% |
| Q1 FY2024 | Mar 31, 2024 | $210.12M | -4.7% |
| Q4 FY2023 | Dec 31, 2023 | $307.06M | +83.4% |
| Q3 FY2023 | Sep 30, 2023 | $196.58M | -9.5% |
| Q2 FY2023 | Jun 30, 2023 | $213.81M | +29.2% |
| Q1 FY2023 | Mar 31, 2023 | $220.38M | +48.2% |
| Q4 FY2022 | Dec 31, 2022 | $167.41M | +1.3% |
| Q3 FY2022 | Sep 30, 2022 | $217.13M | +56.5% |
| Q2 FY2022 | Jun 30, 2022 | $165.53M | +41.9% |
| Q1 FY2022 | Mar 31, 2022 | $148.74M | +26.1% |
| Q4 FY2021 | Dec 31, 2021 | $165.23M | +39.0% |
| Q3 FY2021 | Sep 30, 2021 | $138.74M | +17.2% |
| Q2 FY2021 | Jun 30, 2021 | $116.68M | +55.1% |
| Q1 FY2021 | Mar 31, 2021 | $117.94M | +72.8% |
| Q4 FY2020 | Dec 31, 2020 | $118.86M | +23.2% |
| Q3 FY2020 | Sep 30, 2020 | $118.40M | +65.8% |
| Q2 FY2020 | Jun 30, 2020 | $75.24M | -12.0% |
| Q1 FY2020 | Mar 31, 2020 | $68.26M | +27.4% |
| Q4 FY2019 | Dec 31, 2019 | $96.46M | +12.4% |
| Q3 FY2019 | Sep 30, 2019 | $71.42M | +33.3% |
| Q2 FY2019 | Jun 30, 2019 | $85.52M | +24.4% |
| Q1 FY2019 | Mar 31, 2019 | $53.58M | -4.4% |
| Q4 FY2018 | Dec 31, 2018 | $85.83M | +48.1% |
| Q3 FY2018 | Sep 30, 2018 | $53.59M | +28.3% |
| Q2 FY2018 | Jun 30, 2018 | $68.74M | +43.5% |
| Q1 FY2018 | Mar 31, 2018 | $56.06M | +112.0% |
| Q4 FY2017 | Dec 31, 2017 | $57.95M | +130.7% |
| Q3 FY2017 | Sep 30, 2017 | $41.78M | – |
| Q2 FY2017 | Jun 30, 2017 | $47.89M | – |
| Q1 FY2017 | Mar 31, 2017 | $26.44M | – |
| Q4 FY2016 | Dec 31, 2016 | $25.12M | – |
See a number that looks wrong?